All Blogs

May 02, 2024

Xtant Medical Announced the Launch of SimipliGraft TM and SimpliMaxTM for Chronic and Acute Wounds  On April 30, 2024, Xtant Medical Holdings, Inc., a global medical technology firm specializing in surgical remedies for spinal disorders, announced the complete commercial availability of two amniotic membran...

May 01, 2024

The healthcare market has witnessed a remarkable transformation in recent years, largely driven by rapid advancements in technology and innovation. Among the most notable developments is the evolution of wearable medical devices, which have transcended their traditional roles to become indispensable tools in the mo...

Apr 30, 2024

FDA Greenlights XOLREMDI Capsules from X4 Pharmaceuticals for WHIM Syndrome Treatment X4 Pharmaceuticals has declared that the FDA has granted approval for XOLREMDI™ (mavorixafor) capsules to be utilized in individuals aged 12 and above who have WHIM syndrome (characterized by warts, hypogammaglobulinemia, infec...

Oct 18, 2024

Key Highlights  INVEGA and VRAYLAR (US)/REAGILA (EU) (cariprazine) accounted for the major share of the revenue market for schizophrenia patients in 2023. However, according to DelveInsight, this share is expected to decline by 2034 due to the launch of new emerging therapies. Schizophrenia has a robust...

Apr 29, 2024

VALTOCO, a nasal spray formulation of diazepam, offers enhanced convenience and simplicity for managing seizure clusters, effectively meeting a crucial gap in epilepsy care. This attribute not only empowers individuals to manage their treatment autonomously but also offers reassurance and assistance to caregivers ...

Apr 29, 2024

XEN1101, marks a significant leap forward in the realm of precision medicine for drug-resistant epilepsy, as unlike current treatments that necessitate gradual dosage adjustments, XEN1101 offers the advantage of safe initiation at optimal dosage right from the start.  XEN1101 unveils compelling efficacy wi...

Apr 29, 2024

STACCATO alprazolam, an experimental drug-device amalgamation, heralds a notable progression in epilepsy therapy. Harnessing the STACCATO delivery technology signifies a paradigm shift by facilitating swift seizure cessation within a mere 90 seconds. This achievement is made possible through a handheld inhaler dev...

Apr 26, 2024

2024 could be an eventful year for LUTATHERA and radioligand therapies (RLTs) around their future commercial prospects.  On April 23, 2024, the FDA approved LUTATHERA (lutetium Lu 177 dotatate) for the treatment of pediatric patients aged 12 years and older with somatostatin receptor (SSTR)-positive gastro-...

Apr 26, 2024

AB-1005 represents a pioneering gene therapy utilizing an adeno-associated viral vector serotype 2 (AAV2) to deliver the human glial cell line-derived neurotrophic factor (GDNF) transgene directly into the brain. This innovative technique allows for precise and sustained expression of GDNF, offering promising ther...

Apr 26, 2024

LIBERVANT, a diazepam buccal formulation based on PharmFilm technology serves as a beacon of hope, offering convenient alternatives to existing device-based products, for managing acute repetitive seizure emergencies in young patients. LIBERVANT utilizes "fast-melt strips" for "buccal delivery of...